Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Psoriasis drug has long-term benefits

  • Comment
Long-term use of the psoriasis medication etanercept does not cause more infections or adverse events than placebo, research has shown.

Long-term use of the psoriasis medication etanercept does not cause more infections or adverse events than placebo, research has shown.

The drug also made improvements in Psoriasis Area and Severity Index (PASI) over the course of the 96-week trial.

First, 618 psoriasis patients were given either a placebo or 50 milligrams of etanercept for 12 weeks. Then all 591 continuing patients received etanercept for 84 weeks.

PASI scores peaked at week 48 and at the end of the study, 51.6% of the trial's original etanercept group's scores improved by at least 75%, compared with 51.1% of placebo.

Archives of Dermatology (2007) 143:710-726

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.